Hongbiao Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hongbiao Huang has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- Jinbao Liu
Guangzhou Medical University
21 shared publications Xiaohong Xia
Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China
18 shared publicationsYuning Liao
Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China
17 shared publicationsYuan Liu
Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation School of Basic Medical Sciences Guangzhou Medical University Guangzhou 511436 China
12 shared publicationsCuifu Yu
Shenshan Medical Center Memorial Hospital of Sun Yat‐sen University Shanwei 516600 China
9 shared publicationsNingning Liu
Guangzhou Med Univ, Guangdong Key Lab Vasc Dis, State Key Lab Resp Dis, Guangzhou Inst Cardiovasc Dis,Affiliated Hos 2, Guangzhou 510260, Guangdong, Peoples R China
9 shared publications
Latest Publications
- 29 July 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (36) , 3828-3841
HERC4 synergizes with USP16 to promote lung adenocarcinoma growth by augmenting protein translation via stabilizing RPS15
- 29 July 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (36) , 3828-3841
HERC4 synergizes with USP16 to promote lung adenocarcinoma growth by augmenting protein translation via stabilizing RPS15
- 7 May 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (24) , 2405-2418
The RPS15-DDX21 complex drives prostate malignancy through transcriptional activation of SCD1
Development of castration resistance and distant metastasis remain two major clinical challenges in prostate cancer (PCa) treatment. By analyzing multiple public cancer datasets, we found that ribosomal protein S15 (RPS15) is overexpressed in PCa and related to its metastasis. Beyond its canonical role as a structural component of the ribosome, emerging evidence has highlighted the extraribosomal functions of RPS15 in disease progression. Our study demonstrates that RPS15 significantly promotes proliferation and migration in PCa through the establishment of RPS15 knockdown cells and xenograft models. Mechanistically, RPS15 interacts with the functional domain of DExD-box helicase 21 (DDX21) and facilitates the binding of DDX21 to the transcription start region of stearoyl-CoA desaturase-1 (SCD1), thereby enhancing its transcriptional activity and protein expression to drive the growth, ferroptosis-resistance, and metastasis of PCa cells. Moreover, analysis of clinical samples revealed that RPS15, DDX21, and SCD1 are concomitantly upregulated and exhibit strong positive correlations in PCa tissues. Collectively, our findings uncover the significance of the RPS15-DDX21-SCD1 axis in PCa development, expanding the understanding of noncanonical functions of ribosomal proteins and providing new insights for PCa management.
- 7 May 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (24) , 2405-2418
The RPS15-DDX21 complex drives prostate malignancy through transcriptional activation of SCD1
Development of castration resistance and distant metastasis remain two major clinical challenges in prostate cancer (PCa) treatment. By analyzing multiple public cancer datasets, we found that ribosomal protein S15 (RPS15) is overexpressed in PCa and related to its metastasis. Beyond its canonical role as a structural component of the ribosome, emerging evidence has highlighted the extraribosomal functions of RPS15 in disease progression. Our study demonstrates that RPS15 significantly promotes proliferation and migration in PCa through the establishment of RPS15 knockdown cells and xenograft models. Mechanistically, RPS15 interacts with the functional domain of DExD-box helicase 21 (DDX21) and facilitates the binding of DDX21 to the transcription start region of stearoyl-CoA desaturase-1 (SCD1), thereby enhancing its transcriptional activity and protein expression to drive the growth, ferroptosis-resistance, and metastasis of PCa cells. Moreover, analysis of clinical samples revealed that RPS15, DDX21, and SCD1 are concomitantly upregulated and exhibit strong positive correlations in PCa tissues. Collectively, our findings uncover the significance of the RPS15-DDX21-SCD1 axis in PCa development, expanding the understanding of noncanonical functions of ribosomal proteins and providing new insights for PCa management.
- Open Access
- 27 November 2025
- Published by Springer Nature in Breast Cancer Research
- Vol. 27 (1) , 211
CAND1 mediates CUL7-dependent HER2 protein stability to drive breast cancer progression
HER2-positive breast cancer is a prevalent pathological subtype of breast cancer. Resistance to anti-HER2 targeted therapies remains a significant challeng
- 27 November 2025
- Published by Springer Nature in Breast Cancer Research
- Vol. 27 (1) , 211
Open AccessCAND1 mediates CUL7-dependent HER2 protein stability to drive breast cancer progression
HER2-positive breast cancer is a prevalent pathological subtype of breast cancer. Resistance to anti-HER2 targeted therapies remains a significant challeng
- 3 November 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (48) , 4673-4685
WBP11 inhibits UFL1-mediated UFMylation of NONO to drive hepatocellular carcinoma progression
Identification of novel targets is critical for the effective management of HCC. UFMylation, a novel ubiquitin-like modification, plays an important role in various biological processes and disease progression. We found that WW domain binding protein 11 (WBP11) is enriched and predicts poor prognosis in HCC. Depletion of WBP11 inhibits the malignancy of HCC cells in vitro and in vivo. Mechanistically, the N-terminal of WBP11 interacts with the RNA recognition motif (RRM) domain of Non-POU-domain-containing octamer-binding protein (NONO) and enhances glycolysis in HCC cells. WBP11 maintains protein stability of NONO by competitively inhibiting UFM1-specific ligase 1 (UFL1)-induced UFMylation of NONO at Lys198. Enforced-NONO expression restores the suppression of growth and metastasis caused by WBP11 depletion or UFL1 overexpression. Overall, our study identifies a key role of the WBP11-NONO axis in HCC progression and reveals the importance of UFMylation in cancer, highlighting potential anticancer strategies by targeting the WBP11-regulated new types of posttranslational modifications.
- 3 November 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (48) , 4673-4685
WBP11 inhibits UFL1-mediated UFMylation of NONO to drive hepatocellular carcinoma progression
Identification of novel targets is critical for the effective management of HCC. UFMylation, a novel ubiquitin-like modification, plays an important role in various biological processes and disease progression. We found that WW domain binding protein 11 (WBP11) is enriched and predicts poor prognosis in HCC. Depletion of WBP11 inhibits the malignancy of HCC cells in vitro and in vivo. Mechanistically, the N-terminal of WBP11 interacts with the RNA recognition motif (RRM) domain of Non-POU-domain-containing octamer-binding protein (NONO) and enhances glycolysis in HCC cells. WBP11 maintains protein stability of NONO by competitively inhibiting UFM1-specific ligase 1 (UFL1)-induced UFMylation of NONO at Lys198. Enforced-NONO expression restores the suppression of growth and metastasis caused by WBP11 depletion or UFL1 overexpression. Overall, our study identifies a key role of the WBP11-NONO axis in HCC progression and reveals the importance of UFMylation in cancer, highlighting potential anticancer strategies by targeting the WBP11-regulated new types of posttranslational modifications.
- Open Access
The deubiquitinase USP7 stabilizes HER2 expression and promotes breast cancer progression
- Open Access
- 2 December 2024
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 29 (1) , 1-20
SENP3 mediates deSUMOylation of SIX1 to promote prostate cancer proliferation and migration
Background: Sentrin/SUMO-specific protease 3 (SENP3) is essential to regulate protein stability and function in normal and cancer cells. Nevertheless, its role and action mechanisms in prostate cancer (PCa) remain elusive. Thus, clarification of SENP3’s involvement and the SUMOylation process in PCa is pivotal for discovering potential targets and understanding SUMOylation dynamics. Methods: Cell viability, EdU staining, live cell imaging, and cell cycle assays were used to determine proliferation of PCa cells. Transwell and wound-healing assays were used to detect migration of PCa cells. The interaction between SENP3 and SIX1 was determined by co-immunoprecipitation, western blotting, and immunofluorescence assays. Xenograft models established on NOD-SCID mice were used to evaluate in vivo effects post SENP3 knockdown. Immunohistochemistry was performed to investigate the expression of SENP3 in PCa tissues. Results: This study found that SENP3 is highly expressed in PCa cell lines and tissues from PCa patients. Overexpressed SENP3 is associated with metastatic malignancy in PCa. Various in vivo and in vitro experiments confirmed that SENP3 promotes the proliferation and migration of PCa. In addition, SENP3 interacts with the SD domain of SIX1 and mediates its deSUMOylation and protein stability. Lys154 (K154) is required for the SUMOylation of SIX1. More importantly, SENP3 promotes the malignancy of PCa through the regulation of SIX1. Conclusions: We unravel the significant role of SENP3 in regulating protein stability of SIX1 and progression of PCa, which may deepen our understanding of the SUMOylation modification and provide a promising target for management of metastatic PCa.
- 2 December 2024
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 29 (1) , 1-20
Open AccessSENP3 mediates deSUMOylation of SIX1 to promote prostate cancer proliferation and migration
Background: Sentrin/SUMO-specific protease 3 (SENP3) is essential to regulate protein stability and function in normal and cancer cells. Nevertheless, its role and action mechanisms in prostate cancer (PCa) remain elusive. Thus, clarification of SENP3’s involvement and the SUMOylation process in PCa is pivotal for discovering potential targets and understanding SUMOylation dynamics. Methods: Cell viability, EdU staining, live cell imaging, and cell cycle assays were used to determine proliferation of PCa cells. Transwell and wound-healing assays were used to detect migration of PCa cells. The interaction between SENP3 and SIX1 was determined by co-immunoprecipitation, western blotting, and immunofluorescence assays. Xenograft models established on NOD-SCID mice were used to evaluate in vivo effects post SENP3 knockdown. Immunohistochemistry was performed to investigate the expression of SENP3 in PCa tissues. Results: This study found that SENP3 is highly expressed in PCa cell lines and tissues from PCa patients. Overexpressed SENP3 is associated with metastatic malignancy in PCa. Various in vivo and in vitro experiments confirmed that SENP3 promotes the proliferation and migration of PCa. In addition, SENP3 interacts with the SD domain of SIX1 and mediates its deSUMOylation and protein stability. Lys154 (K154) is required for the SUMOylation of SIX1. More importantly, SENP3 promotes the malignancy of PCa through the regulation of SIX1. Conclusions: We unravel the significant role of SENP3 in regulating protein stability of SIX1 and progression of PCa, which may deepen our understanding of the SUMOylation modification and provide a promising target for management of metastatic PCa.
- Open Access
- 17 November 2024
- Published by Elsevier in Pharmacological Research
- Vol. 210, 107509
METTL14-mediated m6A modification enhances USP22-ERα axis to drive breast cancer malignancy
- 17 November 2024
- Published by Elsevier in Pharmacological Research
- Vol. 210, 107509
Open AccessMETTL14-mediated m6A modification enhances USP22-ERα axis to drive breast cancer malignancy
- 2 November 2024
- Published by Springer Nature in Oncogene
- Vol. 44 (2) , 92-104
The Ku70-SIX1-GPT2 axis regulates alpha-ketoglutarate metabolism to drive progression of prostate cancer
Sine oculis homeobox homolog 1 (SIX1) is a new identified cancer driver in the development of prostate cancer (PC). However, the upstream regulatory mechanisms for SIX1 reactivation in cancer remains elusive. Here, we found that Ku70 robustly interacts with SIX1 in the nucleus of PC cells. The HD domain of SIX1 and the DBD domain of Ku70 are required for formation of Ku70-SIX1 complex. 20 groups of hydrogen bonds were identified in this complex by molecular dynamics simulation. Depletion of Ku70/SIX1 notably abrogates the proliferation and migration of PC. Further studies revealed that SIX1 is recruited to the promoter region on glutamate-pyruvate transaminase 2 (GPT2). Ku70 enhances the SIX1-mediated transcriptional activation on GPT2, thereby facilitating the generation of alpha-ketoglutarate (α-KG). In addition, formation of the Ku70-SIX1 complex promotes GPT2-dependent cell proliferation and migration in PC. Moreover, the expression of GPT2 is upregulated and strongly correlated with the expression of Ku70/SIX1 in PC tissues. In summary, our findings not only provide insight into the mechanistic interactions between Ku70 and SIX1, but also highlight the significance of the Ku70-SIX1-GPT2 axis for α-KG metabolism and PC carcinogenesis.
- 2 November 2024
- Published by Springer Nature in Oncogene
- Vol. 44 (2) , 92-104
The Ku70-SIX1-GPT2 axis regulates alpha-ketoglutarate metabolism to drive progression of prostate cancer
Sine oculis homeobox homolog 1 (SIX1) is a new identified cancer driver in the development of prostate cancer (PC). However, the upstream regulatory mechanisms for SIX1 reactivation in cancer remains elusive. Here, we found that Ku70 robustly interacts with SIX1 in the nucleus of PC cells. The HD domain of SIX1 and the DBD domain of Ku70 are required for formation of Ku70-SIX1 complex. 20 groups of hydrogen bonds were identified in this complex by molecular dynamics simulation. Depletion of Ku70/SIX1 notably abrogates the proliferation and migration of PC. Further studies revealed that SIX1 is recruited to the promoter region on glutamate-pyruvate transaminase 2 (GPT2). Ku70 enhances the SIX1-mediated transcriptional activation on GPT2, thereby facilitating the generation of alpha-ketoglutarate (α-KG). In addition, formation of the Ku70-SIX1 complex promotes GPT2-dependent cell proliferation and migration in PC. Moreover, the expression of GPT2 is upregulated and strongly correlated with the expression of Ku70/SIX1 in PC tissues. In summary, our findings not only provide insight into the mechanistic interactions between Ku70 and SIX1, but also highlight the significance of the Ku70-SIX1-GPT2 axis for α-KG metabolism and PC carcinogenesis.
- Open Access
- 28 July 2023
- Published by Wiley in Advanced Science
- Vol. 10 (27) , e2302025
HSP90β Impedes STUB1‐Induced Ubiquitination of YTHDF2 to Drive Sorafenib Resistance in Hepatocellular Carcinoma
YTH domain family 2 (YTHDF2) is the first identified N6‐methyladenosine (m6A) reader that regulates the status of mRNA. It has been reported that overexpressed YTHDF2 promotes carcinogenesis; yet, its role in hepatocellular carcinoma (HCC) is elusive. Herein, it is demonstrated that YTHDF2 is upregulated and can predict poor outcomes in HCC. Decreased ubiquitination levels of YTHDF2 contribute to the upregulation of YTHDF2. Furthermore, heat shock protein 90 beta (HSP90β) and STIP1 homology and U‐box‐containing protein 1 (STUB1) physically interact with YTHDF2 in the cytoplasm. Mechanically, the large and small middle domain of HSP90β is required for its interaction with STUB1 and YTHDF2. HSP90β inhibits the STUB1‐induced degradation of YTHDF2 to elevate the expression of YTHDF2 and to further boost the proliferation and sorafenib resistance of HCC. Moreover, HSP90β and YTHDF2 are upregulated, while STUB1 is downregulated in HCC tissues. The expression of HSP90β is positively correlated with the YTHDF2 protein level, whereas the expression of STUB1 is negatively correlated with the protein levels of YTHDF2 and HSP90β. These findings deepen the understanding of how YTHDF2 is regulated to drive HCC progression and provide potential targets for treating HCC.
- 28 July 2023
- Published by Wiley in Advanced Science
- Vol. 10 (27) , e2302025
Open AccessHSP90β Impedes STUB1‐Induced Ubiquitination of YTHDF2 to Drive Sorafenib Resistance in Hepatocellular Carcinoma
YTH domain family 2 (YTHDF2) is the first identified N6‐methyladenosine (m6A) reader that regulates the status of mRNA. It has been reported that overexpressed YTHDF2 promotes carcinogenesis; yet, its role in hepatocellular carcinoma (HCC) is elusive. Herein, it is demonstrated that YTHDF2 is upregulated and can predict poor outcomes in HCC. Decreased ubiquitination levels of YTHDF2 contribute to the upregulation of YTHDF2. Furthermore, heat shock protein 90 beta (HSP90β) and STIP1 homology and U‐box‐containing protein 1 (STUB1) physically interact with YTHDF2 in the cytoplasm. Mechanically, the large and small middle domain of HSP90β is required for its interaction with STUB1 and YTHDF2. HSP90β inhibits the STUB1‐induced degradation of YTHDF2 to elevate the expression of YTHDF2 and to further boost the proliferation and sorafenib resistance of HCC. Moreover, HSP90β and YTHDF2 are upregulated, while STUB1 is downregulated in HCC tissues. The expression of HSP90β is positively correlated with the YTHDF2 protein level, whereas the expression of STUB1 is negatively correlated with the protein levels of YTHDF2 and HSP90β. These findings deepen the understanding of how YTHDF2 is regulated to drive HCC progression and provide potential targets for treating HCC.
- Open Access
- 1 January 2023
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 19 (2) , 377-392
Neddylation of HER2 Inhibits its Protein Degradation and promotes Breast Cancer Progression
HER2 is a transmembrane receptor with intrinsic tyrosine kinase activity that is overexpressed in almost 25% of human breast cancers. Here, we report that the neddylation of HER2 is a new post-translational modification that controls its expression and oncogenic activity in human breast cancer. Two critical members in the neddylation pathway, NEDD8 and NEDD8-activating enzyme E1 subunit 1 (NAE1), are detected in human breast specimens. Overexpressed NEDD8 and NAE1 are positively correlated with HER2 expression in human breast cancer. Subsequent structure and function experiments show that HER2 directly interacts with NEDD8 and NAE1, whereas HER2 protein expression is decreased by neddylation depletion. Mechanistically, neddylation inhibition promotes the degradation of HER2 protein by improving its ubiquitination. HER2 overexpression abrogates neddylation depletion-triggered cell growth suppression. The inhibition of neddylation synergized with trastuzumab significantly suppresses growth of HER2 positive breast cancer. Collectively, this study demonstrates a previously undiscovered role of NEDD8-dependent HER2 neddylation promotes tumor growth in breast cancer.
- 1 January 2023
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 19 (2) , 377-392
Open AccessNeddylation of HER2 Inhibits its Protein Degradation and promotes Breast Cancer Progression
HER2 is a transmembrane receptor with intrinsic tyrosine kinase activity that is overexpressed in almost 25% of human breast cancers. Here, we report that the neddylation of HER2 is a new post-translational modification that controls its expression and oncogenic activity in human breast cancer. Two critical members in the neddylation pathway, NEDD8 and NEDD8-activating enzyme E1 subunit 1 (NAE1), are detected in human breast specimens. Overexpressed NEDD8 and NAE1 are positively correlated with HER2 expression in human breast cancer. Subsequent structure and function experiments show that HER2 directly interacts with NEDD8 and NAE1, whereas HER2 protein expression is decreased by neddylation depletion. Mechanistically, neddylation inhibition promotes the degradation of HER2 protein by improving its ubiquitination. HER2 overexpression abrogates neddylation depletion-triggered cell growth suppression. The inhibition of neddylation synergized with trastuzumab significantly suppresses growth of HER2 positive breast cancer. Collectively, this study demonstrates a previously undiscovered role of NEDD8-dependent HER2 neddylation promotes tumor growth in breast cancer.